Risks versus benefits of different types of long-acting injectable antipsychotics

Research output: Contribution to journalReview article

79 Citations (Scopus)

Abstract

Since their introduction into clinical practice in the early 1960s, long-acting depot antipsychotics have been widely used as maintenance therapy for patients with schizophrenia. The improved pharmacokinetics of injectable long-acting antipsychotic therapies have provided more reliable drug delivery and reduced differences in peak and trough plasma levels of the drug. Studies that have compared short-acting oral antipsychotics with long-acting injectable antipsychotics, although imperfect, support injectable antipsychotics as having real benefit over oral antipsychotics on patient outcome owing largely to improved adherence. If patients forget or refuse to take their prescribed oral medications, weeks or months may go by before they experience an exacerbation; the effects of nonadherence become apparent too late to preempt the problem. On the other hand, if a patient fails to show up for an injection, the problem of nonadherence can be immediately addressed. When injectable medi-cation is combined with an active psychosocial treatment program that will respond assertively to nonadherence, relapse rates may be reduced. By preventing or delaying relapse, consistent treatment can improve the patient's quality of life and lead to an overall reduction in the cost of care.

Original languageEnglish (US)
Pages (from-to)15-18
Number of pages4
JournalJournal of Clinical Psychiatry
Volume67
Issue numberSUPPL. 5
StatePublished - Jun 12 2006
Externally publishedYes

Fingerprint

Antipsychotic Agents
Injections
Recurrence
Therapeutics
Pharmaceutical Preparations
Cations
Schizophrenia
Pharmacokinetics
Quality of Life
Costs and Cost Analysis

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Risks versus benefits of different types of long-acting injectable antipsychotics. / McEvoy, Joseph Patrick.

In: Journal of Clinical Psychiatry, Vol. 67, No. SUPPL. 5, 12.06.2006, p. 15-18.

Research output: Contribution to journalReview article

@article{8b501d75ffe24fc49a3779fe2049973e,
title = "Risks versus benefits of different types of long-acting injectable antipsychotics",
abstract = "Since their introduction into clinical practice in the early 1960s, long-acting depot antipsychotics have been widely used as maintenance therapy for patients with schizophrenia. The improved pharmacokinetics of injectable long-acting antipsychotic therapies have provided more reliable drug delivery and reduced differences in peak and trough plasma levels of the drug. Studies that have compared short-acting oral antipsychotics with long-acting injectable antipsychotics, although imperfect, support injectable antipsychotics as having real benefit over oral antipsychotics on patient outcome owing largely to improved adherence. If patients forget or refuse to take their prescribed oral medications, weeks or months may go by before they experience an exacerbation; the effects of nonadherence become apparent too late to preempt the problem. On the other hand, if a patient fails to show up for an injection, the problem of nonadherence can be immediately addressed. When injectable medi-cation is combined with an active psychosocial treatment program that will respond assertively to nonadherence, relapse rates may be reduced. By preventing or delaying relapse, consistent treatment can improve the patient's quality of life and lead to an overall reduction in the cost of care.",
author = "McEvoy, {Joseph Patrick}",
year = "2006",
month = "6",
day = "12",
language = "English (US)",
volume = "67",
pages = "15--18",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "SUPPL. 5",

}

TY - JOUR

T1 - Risks versus benefits of different types of long-acting injectable antipsychotics

AU - McEvoy, Joseph Patrick

PY - 2006/6/12

Y1 - 2006/6/12

N2 - Since their introduction into clinical practice in the early 1960s, long-acting depot antipsychotics have been widely used as maintenance therapy for patients with schizophrenia. The improved pharmacokinetics of injectable long-acting antipsychotic therapies have provided more reliable drug delivery and reduced differences in peak and trough plasma levels of the drug. Studies that have compared short-acting oral antipsychotics with long-acting injectable antipsychotics, although imperfect, support injectable antipsychotics as having real benefit over oral antipsychotics on patient outcome owing largely to improved adherence. If patients forget or refuse to take their prescribed oral medications, weeks or months may go by before they experience an exacerbation; the effects of nonadherence become apparent too late to preempt the problem. On the other hand, if a patient fails to show up for an injection, the problem of nonadherence can be immediately addressed. When injectable medi-cation is combined with an active psychosocial treatment program that will respond assertively to nonadherence, relapse rates may be reduced. By preventing or delaying relapse, consistent treatment can improve the patient's quality of life and lead to an overall reduction in the cost of care.

AB - Since their introduction into clinical practice in the early 1960s, long-acting depot antipsychotics have been widely used as maintenance therapy for patients with schizophrenia. The improved pharmacokinetics of injectable long-acting antipsychotic therapies have provided more reliable drug delivery and reduced differences in peak and trough plasma levels of the drug. Studies that have compared short-acting oral antipsychotics with long-acting injectable antipsychotics, although imperfect, support injectable antipsychotics as having real benefit over oral antipsychotics on patient outcome owing largely to improved adherence. If patients forget or refuse to take their prescribed oral medications, weeks or months may go by before they experience an exacerbation; the effects of nonadherence become apparent too late to preempt the problem. On the other hand, if a patient fails to show up for an injection, the problem of nonadherence can be immediately addressed. When injectable medi-cation is combined with an active psychosocial treatment program that will respond assertively to nonadherence, relapse rates may be reduced. By preventing or delaying relapse, consistent treatment can improve the patient's quality of life and lead to an overall reduction in the cost of care.

UR - http://www.scopus.com/inward/record.url?scp=33744793769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744793769&partnerID=8YFLogxK

M3 - Review article

VL - 67

SP - 15

EP - 18

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - SUPPL. 5

ER -